𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗕𝗶𝗴𝗴𝗲𝘀𝘁 𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 𝗥𝗶𝘀𝗸: 𝟮𝟭 𝗖𝗙𝗥 𝟴𝟮𝟬.𝟭𝟬𝟬(𝗮)
For the past 17+ years, the #1 FDA inspection citation for medical device companies has been the same:
𝗜𝗻𝗮𝗱𝗲𝗾𝘂𝗮𝘁𝗲 𝗖𝗼𝗿𝗿𝗲𝗰𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝘃𝗲 𝗔𝗰𝘁𝗶𝗼𝗻 (𝗖𝗔𝗣𝗔) 𝗽𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀.
FDA’s citations for CAPA systems are due to 4 main gaps:
❌ Lack of documented, implemented, and effective procedures.
❌ Inaccurate or insufficient problem statement and scope
❌ Poor and inadequate investigation and root cause analysis.
❌ Failure to verify that corrective actions were effective.
These weaknesses in CAPA systems are more than audit findings – they’re 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗼𝗿𝘀 𝗼𝗳 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗤𝗠𝗦 𝗴𝗮𝗽𝘀. Left unaddressed, they can escalate into 𝗰𝗼𝘀𝘁𝗹𝘆 𝗿𝗲𝗺𝗲𝗱𝗶𝗮𝘁𝗶𝗼𝗻, 𝘄𝗮𝗿𝗻𝗶𝗻𝗴 𝗹𝗲𝘁𝘁𝗲𝗿𝘀, 𝗰𝗼𝗻𝘀𝗲𝗻𝘁 𝗱𝗲𝗰𝗿𝗲𝗲𝘀, 𝗮𝗻𝗱 𝗱𝗲𝗹𝗮𝘆𝗲𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀.
At 𝗟𝟲𝗘𝗣 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗶𝗻𝗴, we help medical device companies build robust, compliant, and scalable CAPA programs that are:
✅ Fully aligned with 𝟮𝟭 𝗖𝗙𝗥 𝟴𝟮𝟬.𝟭𝟬𝟬 and 𝗙𝗗𝗔 𝗤𝗠𝗦𝗥 (effective February 2026)
✅ Integrated with 𝗜𝗦𝗢 𝟭𝟯𝟰𝟴𝟱:𝟮𝟬𝟭𝟲 – 𝗖𝗹𝗮𝘂𝘀𝗲 𝟴.𝟱 and 𝗜𝗦𝗢 𝟭𝟰𝟵𝟳𝟭 risk-based requirements
✅ Built on industry best practices for 𝗿𝗼𝗼𝘁 𝗰𝗮𝘂𝘀𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀, 𝘁𝗿𝗲𝗻𝗱𝗶𝗻𝗴, 𝗮𝗻𝗱 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗰𝗵𝗲𝗰𝗸𝘀.
Our team specializes in transforming CAPA from a “reactive fix” to a 𝗽𝗿𝗼𝗮𝗰𝘁𝗶𝘃𝗲 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗲𝗻𝗴𝗶𝗻𝗲 that drives continuous improvement and protects patient safety.
A strong CAPA system isn’t just about avoiding FDA 483s — it’s about building a culture of quality, accountability, and profitability through operational excellence.
📩 Connect with our team at 𝗟𝟲𝗘𝗣 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗶𝗻𝗴 to schedule a consultation to discuss your CAPA system.
#FDAinspections #MedTech #QualityAssurance #ComplianceRisk #CAPAdeficiencies
https://lnkd.in/gQKPr2XY
Vice President of Quality, Global Key Solutions | GMP Lead Auditor
4wCan you drop the link to KeyPedia subscription in the chat?